Bingqiu Zhang, Qiang Wang, Chenglong Ouyang, Mei Yang, Qiuxi Chen, Xiaoqiao Chen, Fei Gao, Hui Liu
{"title":"The role and mechanism of tubulin folding cofactor B in glioblastoma migration.","authors":"Bingqiu Zhang, Qiang Wang, Chenglong Ouyang, Mei Yang, Qiuxi Chen, Xiaoqiao Chen, Fei Gao, Hui Liu","doi":"10.1038/s41420-026-03232-6","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma (GBM) is the most common primary malignant brain tumor in the central nervous system, characterized by high invasiveness, incidence, and mortality. Tubulin folding cofactor B (TBCB) is a microtubule-associated regulator implicated in microtubule plus-end organization and related structural features; however, its role and underlying mechanisms in GBM remain unclear. This study aimed to elucidate the function and mechanisms of TBCB in GBM cell proliferation and migration. Analyses of public databases (GEO, TCGA, CGGA) and clinical GBM specimens revealed that TBCB was significantly upregulated in GBM compared with normal controls, with higher expression correlating with higher WHO grades and poor prognosis. Functionally, TBCB knockdown in U87 and U251 cells significantly inhibited proliferation and migration (assessed by EdU, cell counting, Transwell and wound-healing assays) and impaired cell process formation; consistently, in vivo experiments using orthotopic intracranial xenograft models confirmed that TBCB knockdown suppressed tumor growth and prolonged survival. Mechanistically, reciprocal Co-IP/IF supported association of TBCB with both EB1 and EB3, indicating that TBCB acts as a functional partner of the microtubule plus-end tracking proteins ( + TIPs) EB1 and EB3, co-localizing at cell process tips and being associated with microtubule plus-end organization/comet-like features. Furthermore, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis identified the MAPK pathway as a key signaling pathway associated with TBCB; Western blotting showed that TBCB knockdown reduced the p-ERK/ERK ratio, and pharmacological modulation with the ERK agonist TPA and the MEK inhibitor U0126 further indicated that ERK-pathway perturbation regulates TBCB in a time-dependent and nonlinear manner in GBM cells. Collectively, these findings indicate that TBCB promotes GBM cell proliferation and migration through EB1/EB3-associated microtubule plus-end organization and is functionally coupled to the ERK-MAPK pathway in a time-dependent and nonlinear manner, suggesting that TBCB is a candidate regulator of GBM progression that warrants further translational validation.</p>","PeriodicalId":9735,"journal":{"name":"Cell Death Discovery","volume":" ","pages":""},"PeriodicalIF":10.4000,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13586178/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Death Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41420-026-03232-6","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor in the central nervous system, characterized by high invasiveness, incidence, and mortality. Tubulin folding cofactor B (TBCB) is a microtubule-associated regulator implicated in microtubule plus-end organization and related structural features; however, its role and underlying mechanisms in GBM remain unclear. This study aimed to elucidate the function and mechanisms of TBCB in GBM cell proliferation and migration. Analyses of public databases (GEO, TCGA, CGGA) and clinical GBM specimens revealed that TBCB was significantly upregulated in GBM compared with normal controls, with higher expression correlating with higher WHO grades and poor prognosis. Functionally, TBCB knockdown in U87 and U251 cells significantly inhibited proliferation and migration (assessed by EdU, cell counting, Transwell and wound-healing assays) and impaired cell process formation; consistently, in vivo experiments using orthotopic intracranial xenograft models confirmed that TBCB knockdown suppressed tumor growth and prolonged survival. Mechanistically, reciprocal Co-IP/IF supported association of TBCB with both EB1 and EB3, indicating that TBCB acts as a functional partner of the microtubule plus-end tracking proteins ( + TIPs) EB1 and EB3, co-localizing at cell process tips and being associated with microtubule plus-end organization/comet-like features. Furthermore, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis identified the MAPK pathway as a key signaling pathway associated with TBCB; Western blotting showed that TBCB knockdown reduced the p-ERK/ERK ratio, and pharmacological modulation with the ERK agonist TPA and the MEK inhibitor U0126 further indicated that ERK-pathway perturbation regulates TBCB in a time-dependent and nonlinear manner in GBM cells. Collectively, these findings indicate that TBCB promotes GBM cell proliferation and migration through EB1/EB3-associated microtubule plus-end organization and is functionally coupled to the ERK-MAPK pathway in a time-dependent and nonlinear manner, suggesting that TBCB is a candidate regulator of GBM progression that warrants further translational validation.
期刊介绍:
Cell Death Discovery is a multidisciplinary, international, online-only, open access journal, dedicated to publishing research at the intersection of medicine with biochemistry, pharmacology, immunology, cell biology and cell death, provided it is scientifically sound. The unrestricted access to research findings in Cell Death Discovery will foster a dynamic and highly productive dialogue between basic scientists and clinicians, as well as researchers in industry with a focus on cancer, neurobiology and inflammation research. As an official journal of the Cell Death Differentiation Association (ADMC), Cell Death Discovery will build upon the success of Cell Death & Differentiation and Cell Death & Disease in publishing important peer-reviewed original research, timely reviews and editorial commentary.
Cell Death Discovery is committed to increasing the reproducibility of research. To this end, in conjunction with its sister journals Cell Death & Differentiation and Cell Death & Disease, Cell Death Discovery provides a unique forum for scientists as well as clinicians and members of the pharmaceutical and biotechnical industry. It is committed to the rapid publication of high quality original papers that relate to these subjects, together with topical, usually solicited, reviews, editorial correspondence and occasional commentaries on controversial and scientifically informative issues.